Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
G. Lopes
Research Funding - AstraZeneca
J. Segel
No relevant relationships to disclose
D. S. W. Tan
Research Funding - AstraZeneca
Y. Do
Research Funding - AstraZeneca
T. Mok
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca
E. Finkelstein
Research Funding - AstraZeneca